Skip to content
Biotechnology

ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology

ZeptoMetrix 2 mins read

BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.

As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.

"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."

NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.

More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355

Contact Information

Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417

SOURCE: ZeptoMetrix



View the original press release on ACCESS Newswire

Media

More from this category

  • Biotechnology, Medical Health Aged Care
  • 18/07/2025
  • 08:16
Gilead Sciences

Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer

Dr Aeson Chang from Monash University has been awarded 2025 Gilead Sciences Research Scholars Program grant Dr Chang becomes one of only three researchers globally to receive the 2025 grant in the Solid Tumours category Two-year funding will support research exploring the potential role of a common anti-nausea medication in improving breast cancer outcomes, following publication of large-scale observational study Melbourne, Australia – 18 July 2025 – Gilead Sciences Australia today announced that Dr Aeson Chang from the Monash Institute of Pharmaceutical Sciences (MIPS) has been awarded a 2025 Gilead Sciences Research Scholars Program grant of US$180,000 over two years.…

  • Contains:
  • Biotechnology, Science
  • 16/07/2025
  • 13:34
Brandon Capital

Brandon BioCatalyst’s CUREator set to support up to 15 therapeutic biotechs thanks to funding from the Medical Research Future Fund

Brandon BioCatalyst’s CUREator set to support up to 15 therapeutic biotechs thanks to funding from the Medical Research Future Fund Melbourne, Wednesday 16 July:…

  • Contains:
  • Biotechnology
  • 15/07/2025
  • 17:55
Northway Biotech

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.